Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by F. Peng
Total Records ( 2 ) for F. Peng
  C. Zhao , Q. Luo , F. He , F. Peng , X. Xia , F. Huang and X. Yu


To determine the relationship between HbA1c and mean blood glucose concentrations by using HbA1c-mean blood glucose formulae for people on continuous ambulatory peritoneal dialysis.


A total of 305 people on continuous ambulatory peritoneal dialysis, including 13 people with Type 1 diabetes mellitus, 161 people with Type 2 diabetes mellitus and 131 people without diabetes, from a single peritoneal dialysis centre at the First Affiliated Hospital of Sun Yat-sen University, were enrolled between January 2006 and June 2011. Serum HbA1c concentration was measured quarterly and other laboratory variables, including blood glucose, were measured every month. The formulae were established using regression analysis and adjusted for other factors. The estimated blood glucose level calculated using our formulae was compared with that using previous formulae namely the Diabetes Control and Complications Trial and A1c-Derived Average Glucose formulae for people not on dialysis and the Hoshino formula for people on haemodialysis.


The HbA1c-mean blood glucose formulae obtained by linear regression analysis were: 1) mBGmmol/l = 0.107 x HbA1c(mmol/mol) + 1.764 [adjusted R2 (inline image)  = 0.494]; 2) mBGmmol/l = 0.101 x HbA1c (mmol/mol) − 0.001 x Cr (μmol/l) + 2.850 (inline image = 0.507); 3) mBGmmol/l = 0.102 x HbA1c (mmol/mol) − 0.095 x Alb (g/l) + 5.394 (inline image = 0.521); and 4) mBGmmol/l  = 0.099 x HbA1c (mmol/mol) − 0.001 x Cr (μmol/l)−0.084 x Alb (g/l) + 5.754 (inline image = 0.526), where mBG is mean blood glucose, Cr is serum creatinine and Alb is serum albumin. These new formulae performed as well as or better than previous formulae.


The relationship between HbA1c and mean blood glucose for people on continuous ambulatory peritoneal dialysis differs from that for people not on dialysis or for those on haemodialysis. Clinicians and patients can determine glycaemic control targets by applying our formulae.

  G. Lan , L. Peng , X. Xie , F. Peng , Y. Wang and S. Yu
  Bone loss is a common complication among renal transplant patients. Some studies have shown that alendronate may be effective to treat bone loss in these patients. In this study, we have reported our experience with administration of alendronate to treat bone loss in renal transplanted patients.

Methods: The 46 kidney transplant recipients with bone loss were randomly divided into 2 groups: group I was treated with calcium and calcitriol, and group II with calcium, calcitriol, and alendronate. We examined bone mineral density (BMD) and biochemical indicators of both groups. All patients received cyclosporine and prednisone treatment.

Results: There was no significant difference in age, body mass index, gender, immunosuppression, time since transplantation, 25(OH)D3, or intact parathyroid hormone levels at study commencement. The BMD of the femoral neck was significantly increased (P < .05), and the serum type I collagen-cross-linked N telopeptide (NTx) dramatically (P < .05) decreased in posttransplantation group II recipients treated with calcium, calcitriol, and alendronate. There were also significant differences in BMD and serum NTx between recipients treated with versus without alendronate (P < .05).

Conclusion: At least in the short term, alendronate is a effective inhibitor for the treatment of bone loss in renal transplantation patients.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility